Higher CD4/CD8 ratio of pleural effusion predicts better survival for lung cancer patients receiving immune checkpoint inhibitors

Abstract Pleural effusion is a rare immune-related adverse event for lung cancer patients receiving immune checkpoint inhibitors (ICIs). We enrolled 281 lung cancer patients treated with ICIs and 17 were analyzed. We categorized the formation of pleural effusion into 3 patterns: type 1, rapid and ma...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Po-Hsin Lee, Tsung-Ying Yang, Kun-Chieh Chen, Yen-Hsiang Huang, Jeng-Sen Tseng, Kuo-Hsuan Hsu, Yu-Chen Wu, Ko-Jiunn Liu, Gee-Chen Chang
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/f228d1a7f51f4cfea43483e9f6b1b3c4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f228d1a7f51f4cfea43483e9f6b1b3c4
record_format	dspace
spelling	oai:doaj.org-article:f228d1a7f51f4cfea43483e9f6b1b3c42021-12-02T14:53:42ZHigher CD4/CD8 ratio of pleural effusion predicts better survival for lung cancer patients receiving immune checkpoint inhibitors10.1038/s41598-021-89043-42045-2322https://doaj.org/article/f228d1a7f51f4cfea43483e9f6b1b3c42021-04-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-89043-4https://doaj.org/toc/2045-2322Abstract Pleural effusion is a rare immune-related adverse event for lung cancer patients receiving immune checkpoint inhibitors (ICIs). We enrolled 281 lung cancer patients treated with ICIs and 17 were analyzed. We categorized the formation of pleural effusion into 3 patterns: type 1, rapid and massive; type 2, slow and indolent; and type 3, with disease progression. CD4/CD8 ratio of 1.93 was selected as the cutoff threshold to predict survival. Most patients of types 1 and 2 effusions possessed pleural effusion with CD4/CD8 ratios ≥ 1.93. The median OS time in type 1, 2, and 3 patients were not reached, 24.8, and 2.6 months, respectively. The median PFS time in type 1, 2, and 3 patients were 35.5, 30.2, and 1.4 months, respectively. The median OS for the group with pleural effusion CD4/CD8 ≥ 1.93 and < 1.93 were not reached and 2.6 months. The median PFS of those with pleural effusion CD4/CD8 ≥ 1.93 and < 1.93 were 18.4 and 1.2 months. In conclusion, patients with type 1 and 2 effusion patterns had better survival than those with type 3. Type 1 might be interpreted as pseudoprogression of malignant pleural effusion. CD4/CD8 ratio ≥ 1.93 in pleural effusion is a good predicting factor for PFS.Po-Hsin LeeTsung-Ying YangKun-Chieh ChenYen-Hsiang HuangJeng-Sen TsengKuo-Hsuan HsuYu-Chen WuKo-Jiunn LiuGee-Chen ChangNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Po-Hsin Lee Tsung-Ying Yang Kun-Chieh Chen Yen-Hsiang Huang Jeng-Sen Tseng Kuo-Hsuan Hsu Yu-Chen Wu Ko-Jiunn Liu Gee-Chen Chang Higher CD4/CD8 ratio of pleural effusion predicts better survival for lung cancer patients receiving immune checkpoint inhibitors
description	Abstract Pleural effusion is a rare immune-related adverse event for lung cancer patients receiving immune checkpoint inhibitors (ICIs). We enrolled 281 lung cancer patients treated with ICIs and 17 were analyzed. We categorized the formation of pleural effusion into 3 patterns: type 1, rapid and massive; type 2, slow and indolent; and type 3, with disease progression. CD4/CD8 ratio of 1.93 was selected as the cutoff threshold to predict survival. Most patients of types 1 and 2 effusions possessed pleural effusion with CD4/CD8 ratios ≥ 1.93. The median OS time in type 1, 2, and 3 patients were not reached, 24.8, and 2.6 months, respectively. The median PFS time in type 1, 2, and 3 patients were 35.5, 30.2, and 1.4 months, respectively. The median OS for the group with pleural effusion CD4/CD8 ≥ 1.93 and < 1.93 were not reached and 2.6 months. The median PFS of those with pleural effusion CD4/CD8 ≥ 1.93 and < 1.93 were 18.4 and 1.2 months. In conclusion, patients with type 1 and 2 effusion patterns had better survival than those with type 3. Type 1 might be interpreted as pseudoprogression of malignant pleural effusion. CD4/CD8 ratio ≥ 1.93 in pleural effusion is a good predicting factor for PFS.
format	article
author	Po-Hsin Lee Tsung-Ying Yang Kun-Chieh Chen Yen-Hsiang Huang Jeng-Sen Tseng Kuo-Hsuan Hsu Yu-Chen Wu Ko-Jiunn Liu Gee-Chen Chang
author_facet	Po-Hsin Lee Tsung-Ying Yang Kun-Chieh Chen Yen-Hsiang Huang Jeng-Sen Tseng Kuo-Hsuan Hsu Yu-Chen Wu Ko-Jiunn Liu Gee-Chen Chang
author_sort	Po-Hsin Lee
title	Higher CD4/CD8 ratio of pleural effusion predicts better survival for lung cancer patients receiving immune checkpoint inhibitors
title_short	Higher CD4/CD8 ratio of pleural effusion predicts better survival for lung cancer patients receiving immune checkpoint inhibitors
title_full	Higher CD4/CD8 ratio of pleural effusion predicts better survival for lung cancer patients receiving immune checkpoint inhibitors
title_fullStr	Higher CD4/CD8 ratio of pleural effusion predicts better survival for lung cancer patients receiving immune checkpoint inhibitors
title_full_unstemmed	Higher CD4/CD8 ratio of pleural effusion predicts better survival for lung cancer patients receiving immune checkpoint inhibitors
title_sort	higher cd4/cd8 ratio of pleural effusion predicts better survival for lung cancer patients receiving immune checkpoint inhibitors
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/f228d1a7f51f4cfea43483e9f6b1b3c4
work_keys_str_mv	AT pohsinlee highercd4cd8ratioofpleuraleffusionpredictsbettersurvivalforlungcancerpatientsreceivingimmunecheckpointinhibitors AT tsungyingyang highercd4cd8ratioofpleuraleffusionpredictsbettersurvivalforlungcancerpatientsreceivingimmunecheckpointinhibitors AT kunchiehchen highercd4cd8ratioofpleuraleffusionpredictsbettersurvivalforlungcancerpatientsreceivingimmunecheckpointinhibitors AT yenhsianghuang highercd4cd8ratioofpleuraleffusionpredictsbettersurvivalforlungcancerpatientsreceivingimmunecheckpointinhibitors AT jengsentseng highercd4cd8ratioofpleuraleffusionpredictsbettersurvivalforlungcancerpatientsreceivingimmunecheckpointinhibitors AT kuohsuanhsu highercd4cd8ratioofpleuraleffusionpredictsbettersurvivalforlungcancerpatientsreceivingimmunecheckpointinhibitors AT yuchenwu highercd4cd8ratioofpleuraleffusionpredictsbettersurvivalforlungcancerpatientsreceivingimmunecheckpointinhibitors AT kojiunnliu highercd4cd8ratioofpleuraleffusionpredictsbettersurvivalforlungcancerpatientsreceivingimmunecheckpointinhibitors AT geechenchang highercd4cd8ratioofpleuraleffusionpredictsbettersurvivalforlungcancerpatientsreceivingimmunecheckpointinhibitors
_version_	1718389423137095680

Higher CD4/CD8 ratio of pleural effusion predicts better survival for lung cancer patients receiving immune checkpoint inhibitors

Ejemplares similares